
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adult... OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer. With the addition of OST-tADC, considered a next generation Antibody Drug Conjugate (ADC) platform technology, we will be targeting Ovarian, Lung and Pancreatic cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 9.52380952381 | 1.68 | 2.07 | 1.6 | 580072 | 1.94368019 | CS |
4 | 0.16 | 9.52380952381 | 1.68 | 2.07 | 1.45 | 324348 | 1.76072136 | CS |
12 | 0.27 | 17.1974522293 | 1.57 | 2.49 | 1.12 | 282056 | 1.74821364 | CS |
26 | -2.41 | -56.7058823529 | 4.25 | 7 | 1.12 | 727891 | 2.64463728 | CS |
52 | -2.16 | -54 | 4 | 7 | 1.12 | 464386 | 2.76068856 | CS |
156 | -2.16 | -54 | 4 | 7 | 1.12 | 464386 | 2.76068856 | CS |
260 | -2.16 | -54 | 4 | 7 | 1.12 | 464386 | 2.76068856 | CS |
Symbol | Price | Vol. |
---|---|---|
AAPXT Rex 2X Long Apple Daily Target ETF | $ 18.02 (0.00%) | 0 |
AAPWRoundhill AAPL WeeklyPay ETF | $ 35.2026 (0.00%) | 0 |
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026 | $ 26.996 (0.00%) | 0 |
AAAUGoldman Sachs Physical Gold ETF Shares | $ 33.465 (0.00%) | 0 |
AAAAlternative Access First Priority CLO Bond ETF | $ 25.00 (0.00%) | 0 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions